Cours Exicure Inc Other OTC
Actions
US30205M1018
Recherche biotechnologique et médicale
CA 2021 | -483 k -440 k | CA 2022 | 28,83 M 26,24 M | Capitalisation | 5,71 M 5,2 M |
---|---|---|---|---|---|
Résultat net 2021 | -64 M -58,26 M | Résultat net 2022 | -2 M -1,82 M | VE / CA 2021 | 8,21 x |
Trésorerie nette 2021 | 24,4 M 22,22 M | Trésorerie nette 2022 | 1,27 M 1,16 M | VE / CA 2022 | 0,15 x |
PER 2021 |
-0,28
x | PER 2022 |
-2,06
x | Employés | - |
Rendement 2021 * |
-
| Rendement 2022 |
-
| Flottant | 54,96% |
Dirigeants | Titre | Age | Depuis |
---|---|---|---|
Paul Kang
CEO | Chief Executive Officer | 63 | 24/02/23 |
Ji-Young Hwang
DFI | Director of Finance/CFO | 47 | 01/12/22 |
Investor Relations Contact | 47 | - |
Administrateurs | Titre | Age | Depuis |
---|---|---|---|
Ji-Young Hwang
DFI | Director of Finance/CFO | 47 | 01/12/22 |
Paul Kang
CEO | Chief Executive Officer | 63 | 24/02/23 |
Hyuk Joon Ko
BRD | Director/Board Member | - | 23/08/23 |
Varia. 1 janv. | Capi. | |
---|---|---|
-2,90% | 103 Md | |
+1,23% | 95,28 Md | |
+1,46% | 22,15 Md | |
-16,03% | 21,02 Md | |
-8,58% | 18,15 Md | |
-38,74% | 16,73 Md | |
-13,51% | 16,05 Md | |
+4,81% | 13,68 Md | |
+32,94% | 12,17 Md |